Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction

European Journal of Cardio-thoracic Surgery

Volumn 37, Issue 2, 2010, Pages 420-425

  Marasco, Silvana F ^a,b   Pilcher, David ^a   Oto, Takahiro ^a   Chang, Wenly ^b   Griffiths, Anne ^a   Pellegrino, Vince ^a   Chan, Justin ^a   Bailey, Michael ^b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antifibrinolytic agent; Lung transplantation; Reperfusion injury

Indexed keywords

APROTININ;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GRAFT DYSFUNCTION; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURGICAL MORTALITY;

ADULT; APROTININ; CREATININE; EPIDEMIOLOGIC METHODS; FEMALE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; KIDNEY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PRIMARY GRAFT DYSFUNCTION; SERINE PROTEINASE INHIBITORS; YOUNG ADULT;

EID: 74149086318     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.08.007     Document Type: Article

References (19)

1. Brown J.R., Birkmeyer N.J.O., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
2. Kesten S., de Hoyas A., Chaparro C., Westney G., Winton T., and Maurer J.R. Aprotinin reduces blood loss in lung transplant recipients. Ann Thorac Surg 59 4 (1995) 877-879
3. Balsara K.R., Morowich S.T., Lin S.S., Davis R.D., Phillips-Bute B.G., Hartwig M., Appel J.Z., and Welsby I.J. Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation. Interact Cardiovasc Thorac Surg 8 (2009) 45-48
4. Bittner H.B., Richter M., Kuntze T., Rahmel A., Dahlberg P., Hertz M., and Mohr F.W. Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation. Eur J Cardiothorac Surg 29 (2006) 210-215
5. Mathias M.A., Tribble C.G., Dietz J.F., Nguyen R.P., Shockey K.S., Kern J.A., and Kron I.L. Aprotinin improves pulmonary function during reperfusion in an isolated lung model. Ann Thorac Surg 70 (2000) 1671-1674
6. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
7. Mangano D.T., Miao Y., Vuylsteke A., Tudor I.C., Juneja R., Filipescu D., Hoeft A., Fontes M.L., Hillel Z., Ott E., Titov T., Dietzel C., and Levin J. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 5 (2007) 471-479
8. Fergusson D.A., Hebert P.C., Mazer D., Fremes S., MacAdams C., Murkin J.M., Teoh K., Duke P.C., Arellano R., Blajchman M.A., Bussieres J.S., Cote D., Karski J., Martineau R., Robblee J.A., Rodger M., Wells G., Clinch J., and Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
9. Christie J.D., Sager J.S., Kimmel S.E., Ahya V.N., Gaughan C., Blumenthal N.P., and Kotloff R.M. Impact of primary graft failure on outcomes following lung transplantation. Chest 127 (2005) 161-165
10. Rubin D.B. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 26 1 (2007) 20-36
11. Christie J.D., Bavaria J.E., Palevsky H.I., Litzky L., Blumenthal N.P., Kaiser L.R., and Kotloff R.M. Primary graft failure following lung transplantation. Chest 114 (1998) 51-60
12. King R.C., Binns O.A., Rodriguez F., Kanithanon R.C., Daniel T.M., Spotnitz W.D., Tribble C.G., and Kron I.L. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 69 (2000) 1681-1685
13. Fiser S.M., Tribble C.G., Long S.M., Kaza A.K., Kern J.A., Jones D.R., Robbins M.K., and Kron I.L. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 73 (2002) 1041-1047
14. Roberts R.F., Nishanian G.P., Carey J.N., Darbinian S.H., Kim J.D., Sakamaki Y., Chang J.Y., Starnes V.A., and Barr M.L. Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury. Ann Thorac Surg 66 (1998) 225-230
15. Shimoyama T., Tabuchi N., Kojima K., Akamatsu H., Arai H., Tanaka H., and Sunamori M. Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18-hours preservation. Eur J Cardiothorac Surg 28 (2005) 581-587
16. Wittwer T., Wahlers T., Elki S., and Haverich A. Aprotinin enhanced lung preservation solutions: is it worthwhile?. Ann Thorac Surg 67 (1999) 1536-1544
17. Eren S., Esme H., Balci A., Cakir O., Buyukbayram H., Eren M., Erdinc L., and Satici O. The effect of aprotinin on ischemia-reperfusion injury in an in situ normothermic ischemic lung model. Eur J Cardiothorac Surg 23 1 (2003) 60-65
18. Lemmer Jr. J.H., Stanford W., Bonney S.L., Chomka E.V., Karp R.B., Laub G.W., Rumberger J.A., and Schaff H.V. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 59 1 (1995) 132-136
19. Goldstein D.J., Seldomridge J.A., Chen J.M., Catanese K.A., DeRosa C.M., Weinberg A.D., Smith C.R., Rose E.A., Levin H.R., and Oz M.C. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 59 5 (1995) 1063-1067